The anticoagulant drug Xarelto has received U.S. Food and Drug Administration (FDA) approval for treatment of non-valvular atrial fibrillation, deep vein thrombosis and pulmonary embolism.
The drug has been promoted as an improvement on earlier anti-coagulant drugs such as warfarin because it does not require close monitoring of the patient and frequent testing.
However, since its release onto the market, Xarelto has been associated with cases involving uncontrolled bleeding, or hemorrhaging, in the brain and other areas of the body.
The risks associated with an uncontrolled bleeding event are made worse when the patient has been taking Xarelto, as there is no current antidote that is capable of stopping the bleeding. The hemorrhaging will continue until the drug is finally out of the body. However, by then, it may be too late for the patient.
Blood pooling in the brain or around the spinal cord can mean death and permanent impairments. The companies behind the drug, Bayer HealthCare and Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), report that they are waiting on other companies to come up with an antidote that could halt the uncontrolled bleeding events associated with Xarelto.
The drug has been associated with several types of uncontrolled bleeding events, including the following:
Bleeding inside the skull is exceptionally dangerous to the health of the patient. As the blood pools, pressure is put on the brain through compression, reducing blood supply to the brain. The initial symptoms are severe headaches, vomiting, weakness and unconsciousness. The condition will often be fatal if not treated immediately.
Bleeding in the gastrointestinal tract has been associated with the use of Xarelto. The bleeding could occur in any section of the tract, from the esophagus, stomach and small intestines. The risk of serious of fatal bleeding events is made worse by the fact that there is no current antidote for the uncontrolled bleeding due to the presence of Xarelto in the system of the patient.
There are very serious risks associated with blood clots in and around the spinal cord for patients who are undergoing a spinal tap or receiving spinal anesthesia (epidural). The blood clot that could form in this area of the body may lead to paralysis and permanent impairment.
At Salvi, Schostok & Pritchard P.C., our legal team is focused on helping people who have suffered serious side effects after being prescribed Xarelto, including hemorrhaging. We are aggressive in taking on major drug companies and standing up for the rights of injured patients and their families in Chicago and across Illinois. Call or contact us online today for immediate assistance.
Sources / More Information